FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968211431> ?p ?o ?g. }

• W1968211431 endingPage "449" @default.
• W1968211431 startingPage "441" @default.
• W1968211431 abstract "Background Because a significant percentage of patients who require high-dose statin therapy for dyslipidemia experience treatment-related muscle symptoms and an inconsistent clinical response, alternative or adjunctive approaches to the management of dyslipidemia are needed. One alternative approach, antisense therapy, may offer an effective and well-tolerated option for patients not satisfactorily responsive to or intolerant to standard pharmacologic dyslipidemia therapies. Objective This review provides an overview of antisense technology and its potential role in the management of dyslipidemia. Methods Source material was obtained primarily from the published literature identified through a search of the PubMed database. Results Antisense technology is an evolving approach to therapy that has gone through a series of refinements to enhance molecular stability, potency, and tolerability. Mipomersen is an antisense molecule capable of producing clinically meaningful reductions in low-density lipoprotein cholesterol in patients with severe familial hypercholesterolemia. Further long-term clinical studies are required to more clearly quantify its impact on risk for cardiovascular events and establish whether it increases risk for hepatosteatosis. Conclusion Antisense therapy represents a potentially effective and well-tolerated emerging treatment modality for numerous diseases. In the treatment of hypercholesterolemia, the antisense therapy mipomersen may provide a possible treatment option for patients with treatment-resistant dyslipidemia. Because a significant percentage of patients who require high-dose statin therapy for dyslipidemia experience treatment-related muscle symptoms and an inconsistent clinical response, alternative or adjunctive approaches to the management of dyslipidemia are needed. One alternative approach, antisense therapy, may offer an effective and well-tolerated option for patients not satisfactorily responsive to or intolerant to standard pharmacologic dyslipidemia therapies. This review provides an overview of antisense technology and its potential role in the management of dyslipidemia. Source material was obtained primarily from the published literature identified through a search of the PubMed database. Antisense technology is an evolving approach to therapy that has gone through a series of refinements to enhance molecular stability, potency, and tolerability. Mipomersen is an antisense molecule capable of producing clinically meaningful reductions in low-density lipoprotein cholesterol in patients with severe familial hypercholesterolemia. Further long-term clinical studies are required to more clearly quantify its impact on risk for cardiovascular events and establish whether it increases risk for hepatosteatosis. Antisense therapy represents a potentially effective and well-tolerated emerging treatment modality for numerous diseases. In the treatment of hypercholesterolemia, the antisense therapy mipomersen may provide a possible treatment option for patients with treatment-resistant dyslipidemia." @default.
• W1968211431 created "2016-06-24" @default.
• W1968211431 creator A5054876477 @default.
• W1968211431 date "2011-11-01" @default.
• W1968211431 modified "2023-09-28" @default.
• W1968211431 title "Antisense therapy and emerging applications for the management of dyslipidemia" @default.
• W1968211431 cites W1493046933 @default.
• W1968211431 cites W1968949098 @default.
• W1968211431 cites W1990488060 @default.
• W1968211431 cites W2009095926 @default.
• W1968211431 cites W2010033213 @default.
• W1968211431 cites W2025787794 @default.
• W1968211431 cites W2026050954 @default.
• W1968211431 cites W2034180036 @default.
• W1968211431 cites W2042817696 @default.
• W1968211431 cites W2045653120 @default.
• W1968211431 cites W2045895711 @default.
• W1968211431 cites W2052973382 @default.
• W1968211431 cites W2057070125 @default.
• W1968211431 cites W2073760443 @default.
• W1968211431 cites W2084787174 @default.
• W1968211431 cites W2099074546 @default.
• W1968211431 cites W2105962383 @default.
• W1968211431 cites W2120714708 @default.
• W1968211431 cites W2123303862 @default.
• W1968211431 cites W2125673458 @default.
• W1968211431 cites W2125958550 @default.
• W1968211431 cites W2127791131 @default.
• W1968211431 cites W2133380348 @default.
• W1968211431 cites W2136180305 @default.
• W1968211431 cites W2137207585 @default.
• W1968211431 cites W2141137906 @default.
• W1968211431 cites W2150733107 @default.
• W1968211431 cites W2152374411 @default.
• W1968211431 cites W2154210359 @default.
• W1968211431 cites W2170411600 @default.
• W1968211431 cites W2171776498 @default.
• W1968211431 cites W2315506042 @default.
• W1968211431 cites W2340893422 @default.
• W1968211431 cites W2943032204 @default.
• W1968211431 cites W4242375217 @default.
• W1968211431 cites W4251161438 @default.
• W1968211431 cites W4376596304 @default.
• W1968211431 cites W91603961 @default.
• W1968211431 doi "https://doi.org/10.1016/j.jacl.2011.08.007" @default.
• W1968211431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22108147" @default.
• W1968211431 hasPublicationYear "2011" @default.
• W1968211431 type Work @default.
• W1968211431 sameAs 1968211431 @default.
• W1968211431 citedByCount "27" @default.
• W1968211431 countsByYear W19682114312012 @default.
• W1968211431 countsByYear W19682114312013 @default.
• W1968211431 countsByYear W19682114312014 @default.
• W1968211431 countsByYear W19682114312015 @default.
• W1968211431 countsByYear W19682114312016 @default.
• W1968211431 countsByYear W19682114312017 @default.
• W1968211431 countsByYear W19682114312018 @default.
• W1968211431 countsByYear W19682114312019 @default.
• W1968211431 countsByYear W19682114312021 @default.
• W1968211431 countsByYear W19682114312023 @default.
• W1968211431 crossrefType "journal-article" @default.
• W1968211431 hasAuthorship W1968211431A5054876477 @default.
• W1968211431 hasConcept C126322002 @default.
• W1968211431 hasConcept C129312508 @default.
• W1968211431 hasConcept C14363569 @default.
• W1968211431 hasConcept C177713679 @default.
• W1968211431 hasConcept C197934379 @default.
• W1968211431 hasConcept C2778096610 @default.
• W1968211431 hasConcept C2778163477 @default.
• W1968211431 hasConcept C2778375690 @default.
• W1968211431 hasConcept C2779120738 @default.
• W1968211431 hasConcept C2779134260 @default.
• W1968211431 hasConcept C2908938912 @default.
• W1968211431 hasConcept C535046627 @default.
• W1968211431 hasConcept C54355233 @default.
• W1968211431 hasConcept C552990157 @default.
• W1968211431 hasConcept C60644358 @default.
• W1968211431 hasConcept C71924100 @default.
• W1968211431 hasConcept C86803240 @default.
• W1968211431 hasConceptScore W1968211431C126322002 @default.
• W1968211431 hasConceptScore W1968211431C129312508 @default.
• W1968211431 hasConceptScore W1968211431C14363569 @default.
• W1968211431 hasConceptScore W1968211431C177713679 @default.
• W1968211431 hasConceptScore W1968211431C197934379 @default.
• W1968211431 hasConceptScore W1968211431C2778096610 @default.
• W1968211431 hasConceptScore W1968211431C2778163477 @default.
• W1968211431 hasConceptScore W1968211431C2778375690 @default.
• W1968211431 hasConceptScore W1968211431C2779120738 @default.
• W1968211431 hasConceptScore W1968211431C2779134260 @default.
• W1968211431 hasConceptScore W1968211431C2908938912 @default.
• W1968211431 hasConceptScore W1968211431C535046627 @default.
• W1968211431 hasConceptScore W1968211431C54355233 @default.
• W1968211431 hasConceptScore W1968211431C552990157 @default.
• W1968211431 hasConceptScore W1968211431C60644358 @default.
• W1968211431 hasConceptScore W1968211431C71924100 @default.
• W1968211431 hasConceptScore W1968211431C86803240 @default.
• W1968211431 hasIssue "6" @default.
• W1968211431 hasLocation W19682114311 @default.

• next